TY - JOUR
T1 - Cancer cure for 32 cancer types
T2 - Results from the EUROCARE-5 study
AU - EUROCARE-5 Working Group
AU - Dal Maso, Luigino
AU - Panato, Chiara
AU - Tavilla, Andrea
AU - Guzzinati, Stefano
AU - Serraino, Diego
AU - Mallone, Sandra
AU - Botta, Laura
AU - Boussari, Olayidé
AU - Capocaccia, Riccardo
AU - Colonna, Marc
AU - Crocetti, Emanuele
AU - Dumas, Agnes
AU - Dyba, Tadek
AU - Franceschi, Silvia
AU - Gatta, Gemma
AU - Gigli, Anna
AU - Giusti, Francesco
AU - Jooste, Valerie
AU - Minicozzi, Pamela
AU - Neamtiu, Luciana
AU - Romain, Gaëlle
AU - Zorzi, Manuel
AU - De Angelis, Roberta
AU - Francisci, Silvia
N1 - Funding Information:
This work was supported by the Italian Association of Cancer Research (AIRC, grant number 21879); the European Commission (work programme 2017, grant number 801520 HP-JA-2017 Innovative Partnership for Action Against Cancer'); Compagnia di San Paolo, Italy (grant number 2010.1354); and the Cariplo Foundation, Italy (grant number 2010-1984). The funding sources had no active role in study design, collection, analysis and interpretation of data, writing the report or the decision to submit the article for publication.
Publisher Copyright:
© 2020 The Author(s); all rights reserved. Published by Oxford University Press on behalf of the International Epidemiological Association.
Copyright:
Copyright 2021 Elsevier B.V., All rights reserved.
PY - 2020/10/1
Y1 - 2020/10/1
N2 - Background: Few studies have estimated the probability of being cured for cancer patients. This study aims to estimate population-based indicators of cancer cure in Europe by type, sex, age and period. Methods: 7.2 million cancer patients (42 population-based cancer registries in 17 European countries) diagnosed at ages 15-74 years in 1990-2007 with follow-up to 2008 were selected from the EUROCARE-5 dataset. Mixture-cure models were used to estimate: (i) life expectancy of fatal cases (LEF); (ii) cure fraction (CF) as proportion of patients with same death rates as the general population; (iii) time to cure (TTC) as time to reach 5-year conditional relative survival (CRS) >95%. Results: LEF ranged from 10 years for chronic lymphocytic leukaemia patients to <6 months for those with liver, pancreas, brain, gallbladder and lung cancers. It was 7.7 years for patients with prostate cancer at age 65-74 years and >5 years for women with breast cancer. The CF was 94% for testis, 87% for thyroid cancer in women and 70% in men, 86% for skin melanoma in women and 76% in men, 66% for breast, 63% for prostate and <10% for liver, lung and pancreatic cancers. TTC was <5 years for testis and thyroid cancer patients diagnosed below age 55 years, and <10 years for stomach, colorectal, corpus uteri and melanoma patients of all ages. For breast and prostate cancers, a small excess (CRS < 95%) remained for at least 15 years. Conclusions: Estimates from this analysis should help to reduce unneeded medicalization and costs. They represent an opportunity to improve patients' quality of life.
AB - Background: Few studies have estimated the probability of being cured for cancer patients. This study aims to estimate population-based indicators of cancer cure in Europe by type, sex, age and period. Methods: 7.2 million cancer patients (42 population-based cancer registries in 17 European countries) diagnosed at ages 15-74 years in 1990-2007 with follow-up to 2008 were selected from the EUROCARE-5 dataset. Mixture-cure models were used to estimate: (i) life expectancy of fatal cases (LEF); (ii) cure fraction (CF) as proportion of patients with same death rates as the general population; (iii) time to cure (TTC) as time to reach 5-year conditional relative survival (CRS) >95%. Results: LEF ranged from 10 years for chronic lymphocytic leukaemia patients to <6 months for those with liver, pancreas, brain, gallbladder and lung cancers. It was 7.7 years for patients with prostate cancer at age 65-74 years and >5 years for women with breast cancer. The CF was 94% for testis, 87% for thyroid cancer in women and 70% in men, 86% for skin melanoma in women and 76% in men, 66% for breast, 63% for prostate and <10% for liver, lung and pancreatic cancers. TTC was <5 years for testis and thyroid cancer patients diagnosed below age 55 years, and <10 years for stomach, colorectal, corpus uteri and melanoma patients of all ages. For breast and prostate cancers, a small excess (CRS < 95%) remained for at least 15 years. Conclusions: Estimates from this analysis should help to reduce unneeded medicalization and costs. They represent an opportunity to improve patients' quality of life.
KW - Cancer cure
KW - Europe
KW - Life expectancy
KW - Mixture cure models
KW - Population-based cancer registries
KW - Survival
KW - Time to cure
UR - http://www.scopus.com/inward/record.url?scp=85098741984&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85098741984&partnerID=8YFLogxK
U2 - 10.1093/ije/dyaa128
DO - 10.1093/ije/dyaa128
M3 - Article
C2 - 32984907
AN - SCOPUS:85098741984
VL - 49
SP - 1517
EP - 1525
JO - International Journal of Epidemiology
JF - International Journal of Epidemiology
SN - 0300-5771
IS - 5
ER -